ABPI response to NHS Commercial Framework
The NHS Commercial Framework for New Medicines has been published.
Today’s publication of the NHS commercial framework for new medicines provides welcome clarity on how companies can partner with the NHS and NICE to get new medicines to the patients who need them. Richard Torbett
The 2019 Voluntary Scheme for Branded Medicines Pricing and Access committed NHS England to publish a commercial framework, setting out more operational detail on the commercial arrangements with the pharmaceutical industry.
In response, Richard Torbett, Chief Executive of the ABPI, said:
"Today’s publication of the NHS commercial framework for new medicines provides welcome clarity on how companies can partner with the NHS and NICE to get new medicines to the patients who need them.
"As more new medicines are discovered, we need a system that can provide the right commercial flexibilities and that supports faster uptake and adoption of new treatments.
"The Framework provides important recognition of this, and the ABPI will work closely with NHS England as the Framework is reviewed and developed over time."
- NHS Commercial Framework for New Medicines
Last modified: 20 September 2023
Last reviewed: 20 September 2023
